Have a personal or library account? Click to login
Secondary Haemophagocytic Lymphohistiocytosis – The Differential Diagnosis Dilemma In Paediatrics Cover

Secondary Haemophagocytic Lymphohistiocytosis – The Differential Diagnosis Dilemma In Paediatrics

Open Access
|Apr 2015

References

  1. 1. Lipton JM, Arceci RJ. Histiocytic disorders. In: Hoffman R, Edward B, eds. Hematology: basic principles and practice. 4th ed. Philadelphia: Churchill Livingstone. 2005; 857–67.
  2. 2. Ladisch S. Histiocytosis syndrome in childhood. In: Behrman ER, Kliegman MR, Jenson BH. NELSON Textbook of pediatrics, vol 2, 17th ed. Belgrade: Saunders, Bard 2009; 1727–30. (translated)
  3. 3. Favara BE, Feller AC, Pauli M et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol. 1997; 29(3): 157–66.10.1002/(SICI)1096-911X(199709)29:3<;157::AID-MPO1>3.0.CO;2-C
  4. 4. Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med. 2006; 38(1): 20–31.10.1080/07853890500465189
  5. 5. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012; (63): 233–46.10.1146/annurev-med-041610-134208
  6. 6. Feldmann J, Le Deist F, Ouachée–Chardin M et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2002; 117(4): 965–72.10.1046/j.1365-2141.2002.03534.x
  7. 7. Feldmann J, Callebaut I, Raposo G et al. Munc 13–4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003; 115(4): 461–73.10.1016/S0092-8674(03)00855-9
  8. 8. Ohadi M, Lalloz MR, Sham P et al. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3–22 by homozygosity mapping. Am J Hum Genet. 1999; 64(1): 165–71.10.1086/302187
  9. 9. Dufourcq–Lagelouse R, Jabado N, Le Deist F et al. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21–22 and evidence for heterogeneity. Am J Hum Genet. 1999 Jan; 64(1): 172–9.10.1086/302194
  10. 10. Stepp SE, Dufourcq–Lagelouse R, Le Deist F et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999; 286(5446): 1957–9.10.1126/science.286.5446.1957
  11. 11. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002; 99(1): 61–610.1182/blood.V99.1.61
  12. 12. Ansuini V, Rigante D, Esposito S. Debate around infection–dependent hemophagocytic syndrome in pediatrics. BMC Infect Dis. 2013; (13): 13–15.10.1186/1471-2334-13-15
  13. 13. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis. 2000; 6(6): 601–8.10.3201/eid0606.000608
  14. 14. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection– and malignancy–associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998; 12(2): 435–44.10.1016/S0889-8588(05)70521-9
  15. 15. Danish EH, Dahms BB, Kumar ML. Cytomegalovirus– associated hemophagocytic syndrome. Pediatrics. 1985; 75(2): 280-3.10.1542/peds.75.2.280
  16. 16. Bhatia S, Bauer F, Bilgrami SA. Candidiasis–associated hemophagocytic lymphohistiocytosis in a patient infected with human immunodeficiency virus. Clin Infect Dis. 2003; 37(11): 161–6.10.1086/379615
  17. 17. Watanabe T, Okazaki E, Shibuya H. Influenza A virus– associated encephalopathy with haemophagocytic syndrome. Eur J Pediatr. 2003; 162(11): 799–800.10.1007/s00431-003-1288-6
  18. 18. Kaya Z, Oztürk G, Gürsel T, Bozdayi G. Spontaneous resolution of hemophagocytic syndrome and disseminated intravascular coagulation associated with Parvovirus B19 infection in a previously healthy child. Jpn J Infect Dis. 2005; 58(3): 149–51.
  19. 19. Tuon FF, Gomes VS et al. Hemophagocytic syndrome associated with hepatitis A: case report and literature review. Rev Inst Med Trop Sao Paulo. 2008; 50(2): 123–7.10.1590/S0036-46652008000200012
  20. 20. Brastianos PK, Swanson JW, Torbenson M, Sperati J, Karakousis PC. Tuberculosis–associated haemophagocytic syndrome. Lancet Infect Dis. 2006; 6(7): 447–54.10.1016/S1473-3099(06)70524-2
  21. 21. Cascio A, Giordano S, Dones P, Venezia S, Iaria C, Ziino O. Haemophagocytic syndrome and rickettsial diseases. J Med Microbiol. 2011; 60(Pt 4): 537–42.10.1099/jmm.0.025833-021163825
  22. 22. Gosh JB, Roy M, Bala A. Infection associated with Hemophagocytic Lymphohistiocytosis triggered by nosocomial infection. Oman Med J. 2009; 24(3): 223–5.
  23. 23. Cascio A, Pernice LM et al. Secondary hemophagocytic lymphohistiocytosis in zoonoses. A systematic review. Eur Rev Med Pharmacol Sci. 2012; 16(10): 1324–37.
  24. 24. Gagnaire MH, Galambrun C, Stéphan JL. Hemophagocytic syndrome: a misleading complication of visceral leishmaniasis in children – a series of 12 cases. Pediatrics. 2000; 106(4): E58.10.1542/peds.106.4.e5811015553
  25. 25. Onishi R, Namiuchi S. Hemophagocytic syndrome in a patient with rheumatoid arthritis. Intern Med. 1994; 33(10): 607–11.10.2169/internalmedicine.33.6077827376
  26. 26. Wong KF, Hui PK, Chan JK, Chan YW, Ha SY. The acute lupus hemophagocytic syndrome. Ann Intern Med. 1991; 114(5): 387–90.10.7326/0003-4819-114-5-3871992881
  27. 27. Henter JI, Horhe A, Arico M et al. HLH–2004: Diagnostic an therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Pediatr Blood Cancer. 2007; 48(2): 124–31.10.1002/pbc.2103916937360
  28. 28. Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991; 18(1): 29–33.
  29. 29. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013; 139(6):713–27.10.1309/AJCP4ZDKJ4ICOUAT23690113
  30. 30. Tang YM, Xu XJ. Advances in hemophagocytic lymphohistiocytosis: pathogenesis, early diagnosis/differential diagnosis, and treatment. Scientific World Journal. 2011; 11: 697–708.10.1100/tsw.2011.62572005921442147
  31. 31. Konuş OL, Ozdemir A, Akkaya A, Erbaş G, Celik H, Işik S. Normal liver, spleen and kidney dimensions in neonates, infants, and children: evaluation with sonography. AJR Am J Roentgenol. 1998; 171(6): 1693–8.10.2214/ajr.171.6.98433159843315
  32. 32. Rademacher C, Hartmann D, Spiethoff A, Jakobs R. Ferritin and soluble interleukin–2–receptor in the diagnosis of fever of unknown origin. Dtsch Med Wochenschr. 2014; 139(1-2): 23–7.10.1055/s-0033-135992324390846
  33. 33. Lehmberg K, McClain KL, Janka GE, Allen CE. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2014 Apr 21. [Epub ahead of print] PubMed PMID: 24753034.10.1002/pbc.2505824753034
  34. 34. Imashuku S, Hibi S et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood. 1995; 86(12): 4706–7.10.1182/blood.V86.12.4706.bloodjournal86124706
  35. 35. Wang LL, Hu YX, Chen WF et al. Significance of soluble interleukin-2 receptor and NK cell activity in patients with hemophagocytic lymphohistiocytosis. Zhongguo Shi Yan Xue Ye XueZaZhi. 2012; 20(2): 401–4.
  36. 36. Sloma I, Vincent H, Addebbous A, Rivoisy C, Turhan GA, Michot JM. Haemophagocytic histiocyte in a peripheral blood film. Br J Haematol. 2014; 165(2): 163.10.1111/bjh.1269724372340
  37. 37. Jabado N, McCusker C, BasileGde S. Pediatric hemophagocytic syndromes: a diagnostic and therapeutic challenge. Allergy Asthma Clin Immunol. 2005; 1(4): 142–60.
  38. 38. Kobayashi S, Ito M, Sano H et al. Clinical analysis of combination therapy for febrile neutropenic patients in childhood cancer. Pediatr Int. 2013; 55(1): 65–71.10.1111/ped.1202523240936
  39. 39. Raghavendra M, Hoeg RT, Bottner WA, Agger WA. Management of neutropenic fever during a transition from traditional hematology/oncology service to hospitalist care. WMJ. 2014; 113(2): 53–8.
  40. 40. Hung KC, Chiu HH, Tseng YC et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect. 2003; 36(4): 254–9.
  41. 41. Biondi E, McCulloh R, Alverson B, Klein A, Dixon A, Ralston S. Treatment of Mycoplasma Pneumonia: A Systematic Review. Pediatrics. 2014; 133(6):1081–90.10.1542/peds.2013-3729
  42. 42. Aytaç S, Yildirim I, Ceyhan M et al. Risks and outcome of fungal infection in neutropenic children with hematologic diseases. Turk J Pediatr. 2010; 52(2): 121–5.
  43. 43. Rajajee S, Ashok I, Manwani N, Rajkumar J, Gowrishankar K, Subbiah E. Profile of Hemophagocytic Lymphohistiocytosis; Efficacy of Intravenous Immunoglobulin Therapy. Indian J Pediatr. 2014 May 9. [Epub ahead of print] PubMed PMID: 24806152.10.1007/s12098-014-1461-0
  44. 44. Scott R, Robb-Smith A. Histiocytic medullary reticulosis. Lancet. 1939; (2): 194–8.10.1016/S0140-6736(00)61951-7
  45. 45. Farquhar J, Claireaux A. Familial haemophagocytic reticulosis. Arch Dis Child. 1952; 27(136): 519–525.10.1136/adc.27.136.519198856313008468
  46. 46. Boake WC; Card WH, Kimmey JF. Histiocytic Medullary Reticulosis, Concurrence in Father and Son. Arch Intern Med. 1965; 116(2): 245–52.10.1001/archinte.1965.0387002008501614315657
  47. 47. Henter JI, Ehrnst A, Andersson J, Elinder G. Familial hemophagocytic lymphohistiocytosis and viral infections. Acta Paediatr. 1993; 82(4): 369–372.10.1111/j.1651-2227.1993.tb12699.x8391350
  48. 48. Vaiselbuh SR, Bryceson YT, Allen CE, Whitlock JA, Abla O. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014; 61(7): 1329–35.10.1002/pbc.2501724610771
  49. 49. Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013; 2013: 605–11.10.1182/asheducation-2013.1.60524319239
  50. 50. Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis and treatment. J Pediatr. 2013; 163(5): 1253–9.10.1016/j.jpeds.2013.06.05323953723
  51. 51. Balwierz W, Czogała M, Pawińska–Wasikowska K, Cwiklińska M, Walicka–Soja K. Hemophagocytic lymphohistiocytosis: diagnostic problems in pediatrics. Przegl Lek. 2010; 67(6): 417–24.
  52. 52. Real E, Gomez A, Alcaraz MJ, Saez AI, Pastor E, Grau E. Fulminant hemophagocytic syndrome as presenting feature of T–cell lymphoma and Epstein–Barr virus infection. Haematologica. 2000; 85(4): 439–40.
  53. 53. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol. 2013; 161(5): 609–22.10.1111/bjh.1229323577835
  54. 54. Guo X, Li Q, Zhou CY, Zhao YN. Clinical analysis of Epstein–Barr virus–associated hemophagocytic syndrome in children. Zhongguo Shi Yan Xue Ye XueZa-Zhi. 2013; 21(2): 460–4.
  55. 55. Liapis K, Apostolidis J, Delimpasis S. EBV–associated hemophagocytic syndrome. Am J Hematol. 2011; 86(5): 422.10.1002/ajh.21811
  56. 56. Henter JI, Nennesmo I. Neuropathologic findings and neurologic symptoms in twenty–three children with hemophagocytic lymphohistiocytosis. J Pediatr. 1997; 130(3): 358–65.10.1016/S0022-3476(97)70196-3
  57. 57. Haddad E, Sulis ML, Jabado N, Blanche S, Fischer A, Tardieu M. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood. 1997; 89(3): 794–800.10.1182/blood.V89.3.794
  58. 58. Janković G. Aplastic anemia. In: D. Manojlovic. Internal Medicine, 5th ed. Belgrade: The Institute for Textbooks, 2009; 1019–21.
  59. 59. Čolović M. Leucemias. In: D. Manojlovic. Internal Medicine, 5th ed. Belgrade: The Institute for Textbooks, 2009; 1031–43.
  60. 60. Aulbert E, Fromm H, Hornemann H. Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia. Med Klin (Munich). 1991; 86(6): 297–304.
  61. 61. Huang SC, Chen JS, Cheng CN, Yang YJ. Hypoalbuminaemia is an independent predictor for hemophagocytic lymphohistiocytosis in childhood Epstein–Barr virus– associated infectious mononucleosis. Eur J Haematol. 2012; 89(5): 417–22.10.1111/ejh.1200622897479
  62. 62. Eid A, Keddissi JI, Kinasewitz GT. Hypoalbuminemia as a cause of pleural effusions. Chest 1999; 115(4): 1066-9.10.1378/chest.115.4.106610208209
  63. 63. Tutor JD. Chylothorax in infants and children. Pediatrics. 2014; 133(4):722–33.10.1542/peds.2013-207224685960
  64. 64. Popović G. Pleural effusions: a special review of pleural effusions in extrapulmonary disease. Pneumon 2010; 47(1-2): 73–80.
  65. 65. Kogawa K, Sato H, Asano T et al. Prognostic factors of Epstein–Barr virus–associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group. Pediatr Blood Cancer. 2014; 61(7): 1257–62.10.1002/pbc.2498024535916
  66. 66. Ishii E, Ohga S et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007; 86(1): 58–65.10.1532/IJH97.0701217675268
  67. 67. Chen CJ, Huang YC et al. Hemophagocytic syndrome: a review of 18 pediatric cases. J Microbiol Immunol Infect. 2004; 37(3): 157–63.
  68. 68. Bakhshi S, Pautu JL. EBV associated hemophagocytic lymphohistiocytosis with spontaneous regression. Indian Pediatr. 2005; 42(12): 1253–5.
  69. 69. Imashuku S. Treatment of Epstein–Barr virus–related hemophagocytic lymphohistiocytosis (EBV–HLH); update 2010. J Pediatr Hematol Oncol. 2011; 33(1): 35–9.10.1097/MPH.0b013e3181f84a5221088619
  70. 70. Marsh RA, Jordan MB, Filipovich AH. Reduced–intensity conditioning haematopoetic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward. Br J Haematol. 2011; 154(5): 556–63.10.1111/j.1365-2141.2011.08785.x315566821707584
  71. 71. Shiraishi A, Ohga S, Doi T et al. Treatment choice of immunotherapy or further chemotherapy for Epstein–Barr virus–associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2012; 59(2): 265–70.10.1002/pbc.2403922183955
  72. 72. Balamuth NJ, Nichols KE, Paessler M, Teachey DT. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus–associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 2007; 29(8): 569–73.10.1097/MPH.0b013e3180f61be317762500
DOI: https://doi.org/10.1515/sjecr-2015-0009 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454
Language: English
Page range: 55 - 63
Submitted on: Oct 1, 2014
Accepted on: Dec 29, 2014
Published on: Apr 4, 2015
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2015 Rasa Medovic, Biljana Vuletic, Zorica Raskovic, Aleksandra Simovic, Jelena Nestorovic–Tanaskovic, Zoran Igrutinovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.